VivoSeq
Other

Connective Tissue Disease

9

Pipeline Programs↗

8

Active Trials↗

7

Companies Involved↗

Connective Tissue Disease is an early-stage landscape with 9 programs across 7 companies. The most active players are Changchun GeneScience Pharmaceutical Co., Ltd., Vor Biopharma, Glaxo Dba Glaxosmithkline. 1 therapy is approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

6/100

Mech. Concentration

25/100

Completion Rate

67/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Changchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.

1 program

Phase 2V

Vor Biopharma

1 program

Phase 2G

Glaxo Dba Glaxosmithkline

1 program

Phase 3Roche logo

Roche

1 program

Phase 3GSK logo

GSK

2 programs

PreclinicalBoehringer Ingelheim logo

Boehringer Ingelheim

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

60%

Small molecule

6 of 10 classified programs — the dominant modality here.

40%ALL OTHERSMonoclonal antibody220%Protein / enzyme110%Cell therapy110%

Small molecule leads; the ring shows all 10 classified programs, each share of the total. Modality classified for 100% of 11 pipeline programs.

Analysis

Trial Status

11

clinical trials

Recruiting8 · 73%
Completed2 · 18%
Terminated1 · 9%

Clinical Trials

Trial Activity

11 trials

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease
Recruiting·Changchun GeneScience Pharmaceutical Co., Ltd. logoChangchun GeneScience Pharmaceutical Co., Ltd.·Phase 2·NCT06189495·30 enrolled
Connective Tissue Diseases and Lung Manifestations
Recruiting·MMedical University Innsbruck·N/A·NCT04095351·120 enrolled
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
Recruiting·GSK logoGSK·Phase 3·NCT06716606·514 enrolled
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Qifangfeixian Granules in the Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD)
Recruiting·—·Phase 2/3·NCT06674148·124 enrolled
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
Recruiting·GSK logoGSK·Phase 3·NCT06572384·440 enrolled
A Study to Test Tetrandrine Tablets for Connective Tissue Disease-Related Lung Disease
Recruiting·PPeking University Third Hospital·Phase 4·NCT07319598·100 enrolled
Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia
Recruiting·—·Phase 2·NCT05998759·296 enrolled
Clinical Study on the Safety and Efficacy of CD19-BCMA CAR-T Cell Therapy for Connective Tissue Diseases
Recruiting·GGuangzhou Bio-gene Technology Co., Ltd·N/A·NCT07152223·20 enrolled
Efficacy and Safety of Eltrombopag for Refractory Thrombocytopenia Associated With Connective Tissue Disease
Completed·TTongji Hospital·N/A·NCT06458803·52 enrolled
Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD
Completed·RRoyal Brompton & Harefield NHS Foundation Trust·Phase 2/3·NCT01862926·104 enrolled
Correlation Between Changes in Lung Function and Changes in Cough and Dyspnoea in Nintedanib-treated Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) Patients
Terminated·Boehringer Ingelheim logoBoehringer Ingelheim·N/A·NCT05503030·88 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)